The datasets supporting the conclusions of this article have been deposited in the European Nucleotide Archive (ENA) under the accession code PRJEB17508, <http://www.ebi.ac.uk/ena/data/view/PRJEB17508>. We developed an R package, which contains functions to analyze BAM files of targeted NGS with the BPER method. The package is publicly available under the R package "PlasmaMutationDetector," <https://cran.r-project.org/>. We recommend recalibrating the BAM files with GATK (method section) before applying "PlasmaMutationDetector."

Introduction {#sec007}
============

Lung cancer is the leading cause of cancer-related death worldwide, with 1.8 million new cases in 2012 \[[@pmed.1002199.ref001]\]. More than 50% of lung cancer patients are diagnosed with metastatic disease and have a 5-y survival rate of \<5% \[[@pmed.1002199.ref002]\]. However, the development of novel therapeutic approaches based on predictive biomarkers and the use of targeted therapies have improved the clinical outcome of advanced non-small cell lung cancer (NSCLC) patients \[[@pmed.1002199.ref003]\]. The list of molecular targets is increasing rapidly in adenocarcinomas (*EGFR*, *ALK*, *HER2*, *BRAF*, *MET*, *ROS1*, and *RET*) and to a lesser extent also in squamous-cell carcinomas (*FGFR1* and *PIK3CA*) \[[@pmed.1002199.ref004]\]. Molecular testing is routinely performed on DNA extracted from tumor tissue, i.e., solid biopsy, and more recently on circulating cell-free DNA, i.e., liquid biopsy \[[@pmed.1002199.ref005]\]. Circulating DNA may facilitate the study of spatial and temporal tumor heterogeneity \[[@pmed.1002199.ref006],[@pmed.1002199.ref007]\], the characterization of genetic changes under treatment, and the identification of secondary resistance mechanisms \[[@pmed.1002199.ref008],[@pmed.1002199.ref009]\]. It is also a good candidate for early evaluation of treatment efficacy because of its rapid clearance from plasma \[[@pmed.1002199.ref010],[@pmed.1002199.ref011]\].

In lung cancer, circulating tumor DNA (ctDNA) has been validated as a surrogate material to detect mutations in the gene encoding epidermal growth factor receptor (*EGFR*) at diagnosis \[[@pmed.1002199.ref012]--[@pmed.1002199.ref016]\] and to identify secondary *EGFR* mutations, such as p.T790M or p.C797S, at relapse in patients treated with EGFR inhibitors \[[@pmed.1002199.ref016]--[@pmed.1002199.ref020]\]. The prognostic value of ctDNA has been investigated in different cancer types and is becoming an important topic in lung cancer. The technical challenge of this research is to detect low concentrations of ctDNA, as found in lung cancer, and in clinical situations such as the presence of a low tumor burden. Indeed, by analysis of mutations, ctDNA was identified in only 62% of *EGFR*-mutated lung cancer patients \[[@pmed.1002199.ref012]\], as compared to 92% of *KRAS*-mutated colon-cancer patients \[[@pmed.1002199.ref021]\]. To accurately detect ctDNA, ultra-sensitive methods such as digital PCR (dPCR) \[[@pmed.1002199.ref022],[@pmed.1002199.ref023]\] or optimized ultra-deep next-generation sequencing (NGS) are required \[[@pmed.1002199.ref024]--[@pmed.1002199.ref026]\]. Two issues have to be considered: (1) plasma contains low concentrations of cell-free DNA, and (2) ctDNA is often present at a low allelic ratio. The main interest in NGS is in allowing a broad molecular screen using moderate amounts of template DNA. Such an approach is well adapted to the heterogeneous molecular mechanisms driving lung carcinogenesis, tumor progression, and acquired resistance to therapy. NGS will also allow a wide genetic analysis suitable for unselected patient screening. Moreover, in some specific cases, it can be used to assess the relative disposition of different genetic alterations, such as the *cis* or *trans* positions of *EGFR* p.C797S and p.T790M \[[@pmed.1002199.ref018]\]. For this purpose, we previously developed the base-position error rate (BPER) method, a bioinformatics analytical pipeline dedicated to routine ctDNA testing using ultra-deep targeted NGS at 10,000× (Ion Proton, Thermo Fisher Scientific) \[[@pmed.1002199.ref027]\].

In the present prospective observational study, we tested the clinical utility of liquid biopsy in advanced or metastatic NSCLC patients (*n* = 256 plasma samples from 124 patients). Patients' inclusion was not based on the existence of a defined tumor mutation such as *EGFR* or *KRAS*. Our primary objective was to evaluate the prognostic value of ctDNA positivity before treatment initiation with respect to overall survival (OS). Secondary objectives were to evaluate the prognostic impact of ctDNA concentration at treatment initiation and under treatment. To this end, we quantified the absolute concentration of ctDNA at baseline, at first evaluation (E1), and at time of radiological progression. Finally, we investigated the occurrence of secondary mutations possibly related to treatment resistance.

Materials and Methods {#sec008}
=====================

Patients and Tumor Material {#sec009}
---------------------------

We conducted a prospective, single-centre observational study to evaluate the prognostic value of ctDNA in NSCLC patients. The research was conducted according to the recommendations outlined in the Declaration of Helsinki. The study and written protocol were approved by the relevant Ethics Committee (CPP Ile-de-France II n°2013-06-21 SC). The prospective study plan was respected with regards to the primary objective and all secondary objectives presented here. All patients signed a written informed consent form. Patients with newly diagnosed advanced or metastatic NSCLC and undergoing first-line treatment (*n* = 124) were recruited in the European Georges Pompidou Hospital medical oncology department between June 2013 and November 2015. In order to avoid potential selection bias, patients could be included before molecular testing. Exclusion criteria were previous cancer diagnosed within the last 5 y, inability to undergo medical follow-up, and inability to read or understand the consent form.

Blood samples were collected at baseline (T0) before initiation of therapy (chemotherapy or tyrosine-kinase inhibitor), at first evaluation (6 ± 2 wk; E1), and at time of tumor progression (ToP). Among 109 patients eligible for ctDNA follow-up, 85 underwent their first evaluation at 6 ± 2 wk, 13 received no follow-up evaluation, 7 had their first evaluation either before 1 mo or after 2 mo, and 4 died within the first month. Blood samples were processed within 2 h, and plasma was immediately stored frozen. Clinical data collected prospectively included sex, age, performance status (WHO), smoking history, tumor histological type, TNM tumor stage according to the 7th edition of the Union for International Cancer Control (UICC) classification, description and number of metastatic sites, treatment drugs, dates of initiation and end of treatment, radiological evaluation performed every 2 mo by CT-scan according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, date of progression, and date of death or last follow-up. Tumor burden was estimated using the RECIST baseline sum of longest diameters and categorized as low (≤7.5 cm) or high (\>7.5 cm) as previously described \[[@pmed.1002199.ref028]\].

DNA Extraction from Tumor and Plasma Samples {#sec010}
--------------------------------------------

The QIAmp Circulating Nucleic Acid Kit, QIAamp DNA Mini Kit for FFPE, and QIAamp DNA Blood Mini Kit were used for DNA extraction from 2 mL of plasma, formalin-fixed, paraffin-embedded (FFPE) tumor samples, and cell lines, respectively, according to the manufacturer's instructions (QIAGEN, Les Ulis, France). DNA was quantified using a Qubit 2.0 Fluorometer with a Qubit dsDNA BR Assay Kit for DNA from cell lines and HS Assay Kit for circulating cell-free DNA (Life Technologies--Thermo Fisher Scientific, Saint Aubin, France). All DNA samples used in the study were stored at −20°C before use.

dPCR: Emulsion Generation, Thermal Cycling, and Droplet Analyses {#sec011}
----------------------------------------------------------------

The RainDrop Digital PCR System (RainDance Technologies) was used for the dPCR. Wild-type genomic DNA and cell-line DNA were used as internal controls ([S1 Table](#pmed.1002199.s005){ref-type="supplementary-material"}). The PCR mix was prepared as shown in [S2 Table](#pmed.1002199.s006){ref-type="supplementary-material"}. Fragmented 20-ng DNA from negative and positive controls (Covaris S220 sonicator) and 3--6 μL of plasma DNA were added to the mix prior to compartmentalization into droplets using the RainDrop Source instrument. The samples were thermal cycled ([S3 Table](#pmed.1002199.s007){ref-type="supplementary-material"}) using a BioRad thermal cycler (MJ-Mini, S1000 or C1000 touch). Droplets were loaded into the RainDrop Sense instrument and analyzed using RainDrop Analyst software. To calculate the percentage of mutations, a limit of blank was determined for each assay \[[@pmed.1002199.ref029]\] and applied to all samples as previously described \[[@pmed.1002199.ref027]\].

NGS Analyses and Protocol {#sec012}
-------------------------

Sequencing libraries were prepared from tumor FFPE DNA and from circulating free DNA using Ion AmpliSeq Colon and Lung Cancer Research Panel v2 (Life Technologies--Thermo Fisher Scientific), following the manufacturer's recommendations. The multiplex barcoded libraries were generated with the Ion AmpliSeq Library Kit v2 using 6 μL of plasma cell-free DNA as the input, corresponding to a median of 7.8 ng (range: 1.38--300 ng). Libraries were normalized using the Ion Library Equalizer Kit. The pooled barcoded libraries (maximum: 96) were processed on an Ion Chef System using an Ion PI Hi-Q Chef Kit and then sequenced on an Ion Proton System using an Ion PI Chip Kit v3. The FASTQ sequencing data were processed and aligned to the human genome (hg19) using the Ion-Torrent Suite v4.2.1. The BAM files generated by the Ion Torrent Suite were recalibrated using GATK v3.4--46 for local realignment around indels and base quality recalibration \[[@pmed.1002199.ref030]\]. We then applied the BPER method to the recalibrated BAM files as previously described. This method detects high sensitivity mutations in circulating DNA at allele frequencies of as low as 0.001 for insertions or deletions \>2 bp, and at 0.003 for single nucleotide variations. The BPER method is highly consistent with dPCR for *EGFR* and *KRAS* mutations, kappa 0.90 (0.73--1.06) \[[@pmed.1002199.ref027]\]. It has been implemented within an R package entitled "PlasmaMutationDetector," which is publicly available at <https://cran.r-project.org/package=PlasmaMutationDetector>. We recommend recalibrating the BAM files with GATK \[[@pmed.1002199.ref030]\] before applying "PlasmaMutationDetector."

Absolute Quantification of ctDNA {#sec013}
--------------------------------

ctDNA was quantified using the number of wild-type droplets, the mutation allele frequency (measured by dPCR or NGS), and the DNA extract volume (50 μL), and was normalized to 1 mL plasma. ctDNA concentration was categorized into tertiles defining low (\<0.027 ng/mL), intermediate (0.027--0.50 ng/mL), and high (\>0.50 ng/mL) concentrations.

Proliferative Index {#sec014}
-------------------

Paraffin-embedded tissues were cut into 4-μm sections and placed on Superfrost Plus slides. Samples were incubated for 40 min with the Ki67 antibody (mouse monoclonal antibody, MIB-1 clone from Dako) after an 8-min antigen retrieval step at 95°C in a BenchMark ULTRA IHC Staining Module, which was revealed with DAB peroxidase. The percentage of stained nuclei was assessed on ten adjacent high-power field sections, or on the whole sample for small biopsies. If the staining was heterogeneous, the most proliferative area was taken into account.

Statistical Analysis {#sec015}
--------------------

The sample size (*n* = 102) was calculated to allow detection of an OS difference with a hazard ratio (HR) of 2 between patients with and without ctDNA at baseline, considering a proportion of positive ctDNA patients of 0.6, an overall 2-y survival rate of 0.20, a power of 0.80, and type I error rate of 0.05. Baseline ctDNA was considered positive if detected by NGS or by dPCR. Statistical analyses were performed on the per-protocol population composed of all patients with at least one molecular alteration identified by NGS in the tumor or in the initial plasma sample (*n* = 109).

The cut-off date for analysis was May 2016. Patients were censored at last follow-up. Follow-up time was calculated using the reverse Kaplan-Meyer method. The OS was calculated from the date of treatment initiation until death from any cause. Progression-free survival was calculated from the date of treatment initiation until RECIST radiological progression or death. The Cox proportional-hazards regression model was used to perform univariate and multivariate analyses with a 95% confidence interval (CI). Multivariate analysis was performed using variables associated with the outcome in univariate analysis at a *p*-value of *\<* 0.05.

All statistical analyses were performed using JMP software version 10.0 (SPSS, Chicago, Illinois). A *p*-value \< 0.05 was considered significant.

Results {#sec016}
=======

The flowchart ([Fig 1A](#pmed.1002199.g001){ref-type="fig"}) describes selection of the 109 patients analyzed in this study starting from the total population (*n* = 124). These 109 patients met all the criteria for analysis and follow-up with an identified marker mutation at baseline either in tumor tissue (*n* = 104) or in plasma at T0 (*n* = 5). It is noteworthy that *ALK* or *ROS1* rearrangements cannot be assessed by this NGS panel. As no other marker alteration was identified in patients with *ALK* and *ROS1* tumors, they were excluded. The ctDNA was evaluated at three time points: baseline (T0), first evaluation (i.e., 6 ± 2 wk, E1), and time of progression (ToP) ([Fig 1B](#pmed.1002199.g001){ref-type="fig"}). Patients\' characteristics are described in [Table 1](#pmed.1002199.t001){ref-type="table"}.

![Study design.\
(A) Flowchart of the study population. (B) Time point of ctDNA follow-up. \*Includes ALK fusion (*n* = 3) and ROS1 fusion (*n* = 1). \*\*PIK3CA p.H1047L. ^†^TP53 p.Gly244Cys. ^\$^KRAS p.G12V, TP53 p.C135Y, and TP53 p.R248W. No mutations were found for *AKT1*, *ERBB2*, *FBXW7*, *FGFR2*, *MET*, or *NOTCH1*.](pmed.1002199.g001){#pmed.1002199.g001}

10.1371/journal.pmed.1002199.t001

###### Summary of baseline patient and tumor characteristics.

![](pmed.1002199.t001){#pmed.1002199.t001g}

  Characteristics                       
  -------------------------------- ---- ----
  **Sex**                               
  Male                             49   45
  Female                           60   55
  **Age**                               
  \<70 y                           67   61
  ≥70 y                            42   39
  **Smoking History**                   
  Present or former                73   67
  Never                            36   33
  **Performance Status (WHO)**          
  0--1                             71   65
  2--3                             38   35
  **Histological Types**                
  Nonsquamous NSCLC                98   90
  Squamous NSCLC                   11   10
  **Tumor Stage (UICC 7th ed.)**        
  IIIB                             12   11
  IV                               97   89
  **Tumor Burden (BSLD)**               
  ≤7.5 cm                          66   63
  \>7.5 cm                         39   37
  **Metastatic Sites**                  
  Bone                             52   48
  Liver                            9    8
  Brain                            22   20
  **Mutations**                         
  *TP53*                           65   60
  *EGFR*                           47   43
  *KRAS*                           29   27
  **Treatment Type**                    
  Chemotherapy                     73   67
  EGFR TKI                         36   33

BSLD, baseline sum of longest diameters; TKI, tyrosine kinase inhibitor.

NGS Method for ctDNA Detection {#sec017}
------------------------------

A previous assessment of NGS performance in clinical samples showed a high level of agreement with dPCR for *EGFR* and *KRAS* mutations \[[@pmed.1002199.ref027]\]. In the present study, double testing of 59 patients with *EGFR*-, *KRAS*-, or *BRAF*-mutated tumors confirmed these results ([Fig 2](#pmed.1002199.g002){ref-type="fig"}). The number of patients eligible for NGS ctDNA screening was 105, as compared to 59 when considering only the three recurrent driver alterations ([Fig 2](#pmed.1002199.g002){ref-type="fig"}). The high frequency of *TP53* mutations accounted for most of the gain in eligible patients ([S1 Fig](#pmed.1002199.s001){ref-type="supplementary-material"}).

![Baseline ctDNA detection using NGS.\
On the left, the figure shows *EGFR*, *KRAS*, and *BRAF* mutation testing with dPCR and NGS. On the right, the figure shows the 105 patients eligible for baseline ctDNA NGS testing, among whom 74 were positive.](pmed.1002199.g002){#pmed.1002199.g002}

Baseline ctDNA and Prognosis {#sec018}
----------------------------

Of 109 patients, 4 did not have ctDNA evaluated at baseline. The plasma ctDNA detection rate was 75 (74 by NGS and 1 rescued by dPCR) out of 105 patients (71.4%, 95% CI 60%--82%, [Table 2](#pmed.1002199.t002){ref-type="table"}) at baseline, including 42.9%, 27.6%, and 0.9% with one, two, and three mutations, respectively. Negative baseline ctDNA was associated with a lower incidence of bone metastasis (odds ratio \[OR\] 0.34 \[95% CI 0.14--0.83\]) and lower tumor burden (OR 0.24 \[95% CI 0.08--0.70\]). Nine mutations (8 patients) that were not present in the tumor were detected in ctDNA at T0: one *EGFR* exon 19 deletion, one *EGFR* p.T790M mutation, two *TP53* mutations, two *PTEN* mutations, one ERBB4 mutation, and two *PIK3CA* mutations ([Fig 3](#pmed.1002199.g003){ref-type="fig"}). Technical issues and low-quality FFPE DNA likely represent the main explanations for these discrepancies, although tumor heterogeneity cannot be ruled out.

![Mutations identified in tumor and in baseline plasma samples.\
Comparison of molecular alterations found in tumor tissue and/or in baseline (T0) plasma (*n* = 109 participants).](pmed.1002199.g003){#pmed.1002199.g003}

10.1371/journal.pmed.1002199.t002

###### Plasma characteristics.

![](pmed.1002199.t002){#pmed.1002199.t002g}

  Treatment Time                       Baseline (T0)   First Evaluation (E1)       Time of Progression (ToP)                                  
  ------------------------------------ --------------- --------------------------- --------------------------- ------------------------- ---- ---------------------------
  ctDNA positivity rate (%)            105             71.4% (60--82) (*n* = 75)   85                          32% (19--45) (*n* = 27)   66   71.2% (57--83) (*n* = 47)
  ctDNA concentration (ng/mL plasma)   105             0.12 (0--0.79)              85                          0 (0--0.06)               46   0.09 (0.009--1.23)

IQR, interquartile range.

After a median follow-up of 18.8 mo, 94 and 63 events occurred for progression-free survival (PFS) and OS, respectively. Baseline ctDNA positivity was associated with reduced OS (median 13.6 versus 21.5 mo, *p* = 0.03, [Fig 4](#pmed.1002199.g004){ref-type="fig"}) and poor PFS (median 4.9 versus 10.4 mo, *p* \< 0.001). ctDNA remained associated with a poor outcome in multivariate analyses. HRs were 1.82 (95% CI 1.01--3.55, *p* = 0.045; [Table 3](#pmed.1002199.t003){ref-type="table"}) and 2.14 (95% CI, 1.30--3.67 *p* = 0.002; [S4 Table](#pmed.1002199.s008){ref-type="supplementary-material"}) for OS and PFS, respectively. For OS, ctDNA was independent of performance status, while for PFS, ctDNA was the only prognostic factor that remained independent after adjustment on univariate significant parameters.

![Prognostic impact of positive baseline ctDNA.\
(A) PFS and (B) OS in patients with positive and negative ctDNA (*n* = 105).](pmed.1002199.g004){#pmed.1002199.g004}

10.1371/journal.pmed.1002199.t003

###### Effect of patient and tumor baseline characteristics on OS (n = 109).

![](pmed.1002199.t003){#pmed.1002199.t003g}

  Characteristics                            Univariate Cox Model                        Multivariate Cox Model[\*](#t003fn001){ref-type="table-fn"}                                                                     
  -------------------------------- ---- ---- ------------------------------------------- ------------------------------------------------------------- -------- ------------------------------------------- ------------ -------
  **Sex**                                                                                                                                                                                                                
  Male                             49   45   1                                                                                                                  1                                                        
  Female                           60   55   0.58                                        0.35--0.98                                                    0.04     0.65                                        0.38--1.09   0.10
  **Age**                                                                                                                                                                                                                
  \<70 y                           67   61   1                                                                                                                                                                           
  ≥70 y                            42   39   1.11                                        0.66--1.85                                                    0.68                                                              
  **Smoking History**                                                                                                                                                                                                    
  Present or former                73   67   1                                                                                                                                                                           
  Never                            36   33   0.64                                        0.36--1.09                                                    0.10                                                              
  **Performance Status (WHO)**                                                                                                                                                                                           
  0--1                             71   65   1                                                                                                                  1                                                        
  2--3                             38   35   2.76                                        1.66--4.56                                                    0.0001   2.41                                        1.42--4.04   0.001
  **Histological Types**                                                                                                                                                                                                 
  Nonsquamous NSCLC                98   90   1                                                                                                                                                                           
  Squamous NSCLC                   11   10   1.47                                        0.56--3.17                                                    0.39                                                              
  **Tumor Stage (UICC 7th ed.)**                                                                                                                                                                                         
  IIIB                             12   11   1                                                                                                                                                                           
  IV                               97   89   1.19                                        0.52--3.43                                                    0.70                                                              
  **Tumor Burden (BSLD)**                                                                                                                                                                                                
  ≤7.5 cm                          66   63   1                                                                                                                                                                           
  \>7.5 cm                         39   37   1.38                                        0.82--2.29                                                    0.22                                                              
  **Metastatic Sites**                                                                                                                                                                                                   
  Bone                             52   48   1.07[\*](#t003fn001){ref-type="table-fn"}   0.65--1.76                                                    0.79                                                              
  Liver                            9    8    2.35[\*](#t003fn001){ref-type="table-fn"}   1.02--4.69                                                    0.04     2.07[\*](#t003fn001){ref-type="table-fn"}   0.90--4.21   0.08
  Brain                            22   20   1.62[\*](#t003fn001){ref-type="table-fn"}   0.86--2.88                                                    0.13                                                              
  **Mutations**                                                                                                                                                                                                          
  *TP53*                           65   60   1.49[\*](#t003fn001){ref-type="table-fn"}   0.89--2.57                                                    0.13                                                              
  *EGFR*                           47   43   0.64[\*](#t003fn001){ref-type="table-fn"}   0.37--1.07                                                    0.09                                                              
  *KRAS*                           29   27   1.37[\*](#t003fn001){ref-type="table-fn"}   0.75--2.37                                                    0.29                                                              
  **Baseline ctDNA**                                                                                                                                                                                                     
  Negative                         30   29   1                                                                                                                  1                                                        
  Positive                         75   71   1.97                                        1.09--3.81                                                    0.02     1.82                                        1.01--3.55   .045

\*Relative to patients without the specific characteristic. BSLD, baseline sum of longest diameters.

To study the impact of ctDNA concentration, patients were categorized into tertiles (*n* = 35 patients in each tertile) defining low (\<0.027 ng/mL), intermediate (0.027--0.50 ng/mL), and high (\>0.50 ng/mL) concentration groups. High ctDNA concentration was associated with higher tumor burden as evaluated by RECIST criteria ([Fig 5A](#pmed.1002199.g005){ref-type="fig"}) and with the presence of liver metastases ([Fig 5B](#pmed.1002199.g005){ref-type="fig"}). A multivariate analysis using an ordinal logistic model showed that tumor burden and liver metastasis were independently associated with ctDNA concentration (*p* \< 0.001 and *p* \< 0.008, respectively). Moreover, ctDNA positivity was associated with a higher proliferative index ([Fig 5C](#pmed.1002199.g005){ref-type="fig"}). Concerning prognosis, the median OS was 13.0, 13.4, and 21.5 mo (*p =* 0.03), and the median PFS was 4.1, 5.7 and 10.4 mo (*p* \< 0.001) for the high, intermediate, and low groups, respectively ([S2 Fig](#pmed.1002199.s002){ref-type="supplementary-material"}).

![Clinical characteristics associated with ctDNA concentration.\
Correlation between T0 ctDNA concentration tertiles and (A) tumor burden defined by the sum of the RECIST target lesions (Mann-Whitney test) and (B) presence of liver metastasis (Fisher's exact test). (C) Correlation between positive ctDNA at baseline and Ki67 proliferative index expressed as a % of positive cells in a subset of tumors with available tissue (*n* = 19, Mann-Whitney test). \**p* \< 0.05, \*\**p* \< 0.005, \*\*\**p* \< 0.001.](pmed.1002199.g005){#pmed.1002199.g005}

Monitoring Early Tumor Response Using ctDNA {#sec019}
-------------------------------------------

The number of patients with positive ctDNA at first evaluation (E1) was 27/85 (31%), which is lower than at T0 ([Table 2](#pmed.1002199.t002){ref-type="table"}). Among the positive samples, ctDNA concentration had increased in 13 patients ([Fig 6A](#pmed.1002199.g006){ref-type="fig"}) and decreased in 14 ([Fig 6B](#pmed.1002199.g006){ref-type="fig"}). Among the negative samples (*n* = 58), the ctDNA concentration had normalized in 32 patients ([Fig 6C](#pmed.1002199.g006){ref-type="fig"}) and remained negative in 23 patients ([Fig 6D](#pmed.1002199.g006){ref-type="fig"}). [Fig 6E](#pmed.1002199.g006){ref-type="fig"} shows that the negativity of ctDNA at E1 and not its decrease was the best prognostic marker for PFS. As expected, E1 ctDNA positivity was associated with RECIST tumor progression ([Fig 6F](#pmed.1002199.g006){ref-type="fig"}) and a shorter PFS (median 2.8 versus 9.6 mo, *p* \< 0.001, [Fig 6G](#pmed.1002199.g006){ref-type="fig"}) that translated into shorter OS (median 8.0 versus 23.2 mo, *p* \< 0.001; [Fig 6H](#pmed.1002199.g006){ref-type="fig"}). The survival impact of E1 positivity remained significant both in the subgroup of patients with *KRAS*, *EGFR*, or *TP53* mutations and in the group of patients with more than one alteration ([S3 Fig](#pmed.1002199.s003){ref-type="supplementary-material"}). In an exploratory multivariate analysis on OS, E1 ctDNA positivity (HR 3.27, 95% CI 1.66--6.40, *p* \< 0.001) was independent of the result of the first RECIST evaluation (progressive disease versus stable disease: HR 2.37, 95% CI 1.05--5.28, *p =* 0.03; progressive disease versus complete or partial response: HR 2.69, 95% CI 1.18--6.14, *p* = 0.02).

![Measurement of ctDNA at first evaluation.\
Evolution of ctDNA concentration (ng/mL) between baseline (T0) and first evaluation (E1) showing a (A) decrease, (B) increase, (C) normalization, or (D) negativity at both time points. (E) PFS according to ctDNA evolution between T0 and E1. (F) Waterfall plot for the best changes in RECIST scores (%) according to the E1 ctDNA status. \*Indicates a progressive disease as best response. (G) PFS for E1 ctDNA groups. (H) OS for E1 ctDNA groups.](pmed.1002199.g006){#pmed.1002199.g006}

Tumor Heterogeneity at Time of Tumor Progression (ToP) {#sec020}
------------------------------------------------------

At the ToP, ctDNA was detected in 47/66 patients (71.2%) ([Table 2](#pmed.1002199.t002){ref-type="table"}). The ctDNA evolution at T0, E1, and ToP is shown in [S4 Fig](#pmed.1002199.s004){ref-type="supplementary-material"}. The mean time between biological and radiological progression was 11 ± 9.4 d (*P* .26) in a pairwise analysis of ctDNA and RECIST time to progression. The Kaplan-Meier estimation of median time to ctDNA progression was 139 d (95% CI 92--181) and the median time to RECIST progression was 156 d (95% CI 118--208) ([Fig 7A](#pmed.1002199.g007){ref-type="fig"}).

![ctDNA at tumor progression.\
(A) Time to RECIST progression and time to ctDNA progression in 47 patients with positive ctDNA at time of progression (ToP). (B) Mutations detected in plasma at baseline (T0) and at time of progression (ToP) (*n* = 66 patients). Acquired mutations detected neither in the tumor tissue nor in the T0 plasma are represented as a green square surrounded by blue. Mutations lost at ToP are represented as a grey square.](pmed.1002199.g007){#pmed.1002199.g007}

The mutations found at progression are shown in [Fig 7B](#pmed.1002199.g007){ref-type="fig"}, most of which were present in tumor DNA at the time of diagnosis. However, for acquired mutations, we noticed a recurrent appearance of the p.T790M mutation in the *EGFR*-mutated group but much more diverse types of mutations in the *EGFR* wild-type tumors.

Discussion {#sec021}
==========

Our study suggests that ctDNA detection using high-throughput sequencing technologies is a valuable tool to determine patient prognosis in advanced NSCLC. We have confirmed and extended the prognostic value of ctDNA previously reported by Karachaliou and colleagues in the *EGFR*-mutated subgroup population \[[@pmed.1002199.ref014]\]. Our study shows an additive value of ctDNA in evaluating treatment efficacy when used in parallel with radiological evaluation. Moreover, we found a strong association between ctDNA at first evaluation and treatment benefit in terms of radiological response, PFS, and OS.

Our study has several limitations. Firstly, while the patients were not selected on the basis of tumor mutation, the study population is biased towards an excess of *EGFR* mutations for a white population \[[@pmed.1002199.ref031]\]. However, one-half of the patients had non-*EGFR* mutations, and we found no difference in ctDNA detection rates between *EGFR* and non-*EGFR* mutations. The heterogeneity of our study population in regard to treatment and clinical features does limit the statistical power of our results. From a technical point of view, the NGS panel used was restricted to 22 genes. The use of a comprehensive cancer panel including genes with recurrent mutations in lung cancer, such as *KEAP1* and *NF1*, would certainly be more efficient to identify patients for whom ctDNA follow-up would be possible. Moreover, both these genes have been implicated in secondary resistance to chemotherapy and targeted therapy \[[@pmed.1002199.ref032],[@pmed.1002199.ref033]\]. Increasing the number of markers per individual is expected to increase clinical sensitivity and specificity, as shown by Newman et al. \[[@pmed.1002199.ref034]\]. Our bioinformatics analytical pipeline is applicable to any panel and any sequencing technology following its simple validation using a set of controls to calculate the panel's background noise. However, gene fusions, copy number changes, and \<3 base-pair indels will remain undetected.

One of the main findings of our study is that measurement of ctDNA in plasma under treatment should be interpreted per se and not relative to its baseline concentration. The absence of ctDNA normalization at the first evaluation has a major prognostic impact on both PFS and OS. The ctDNA concentration reported in our study was an absolute measurement as opposed to being a relative percentage measure as with mutant allele fraction (MAF). In some clinical conditions such as infection \[[@pmed.1002199.ref035]\], the MAF might be biased by the presence of large quantities of nontumor circulating DNA. The present study was designed to detect small changes in ctDNA concentration in order to evaluate treatment response. We chose to report the DNA concentrations to avoid biases due to the presence of non-tumor DNA. Because ctDNA clearance appears important for clinical evaluation, MAF is also appropriate to analyze ctDNA dynamics under treatment. Our results are consistent with previous findings showing that ctDNA normalization before the third cycle of treatment in *EGFR*-mutated patients is associated with improved OS \[[@pmed.1002199.ref036],[@pmed.1002199.ref037]\].

Further clinical studies are required to define the best time for ctDNA evaluation and to determine whether patients with positive ctDNA under one treatment might benefit from a treatment change. Previous series have demonstrated a detectable decrease in ctDNA at 15 d after treatment initiation.

It is worth noting that patients with undetectable ctDNA at baseline and those with undetectable ctDNA at first evaluation had a similar prognosis. Those showing ctDNA positivity at diagnosis could have tumors with higher proliferation capacities, as suggested by the higher Ki67 index, higher tumor burden, and increased incidence of metastasis. Concerning liver metastasis, the absence of capillary basal membrane in the liver may also facilitate the release of tumor DNA in the circulation.

In this study, the use of optimized NGS doubled the number of eligible patients for ctDNA follow-up when compared to the use of methods targeting hotspot mutations. The sensitivity of the method we developed was similar to that of dPCR in the range of DNA inputs used in the study. Our evaluations of ctDNA in a clinical setting imposed much lower DNA inputs for dPCR and NGS than is usually used in a research context. The median of 7.8 ng corresponding to 2,363 genomes that we obtained as input was insufficient to achieve a limit of detection \<0.001 in all cases, yet corresponds to inputs from clinical specimens \[[@pmed.1002199.ref029]\]. The development of automated DNA extraction methods from larger plasma volumes followed by a DNA concentration step would likely enhance ctDNA detection. The detection of ctDNA in 71% of patients was nevertheless consistent with previous studies \[[@pmed.1002199.ref012]\]. Patients with negative or positive ctDNA at baseline had similar concentrations of total circulating DNA, thus rendering unlikely the possibility of a technical issue.

At the ToP, ctDNA was detected within the same proportion of patients as compared to baseline. The tumor heterogeneity captured by ctDNA NGS analysis was stronger for *EGFR* wild-type tumors and may reflect tobacco or chemotherapy-induced molecular heterogeneity. The sole use of dPCR limits the study to a few alterations and might not identify molecular heterogeneity at progression.

Conclusion {#sec022}
----------

This prospective study showed that ctDNA is a marker of prognosis at baseline and its normalization at first evaluation is associated with treatment benefit in metastatic NSCLC patients. Our BPER-method targeted NGS has thus been validated in a clinical setting to detect ctDNA and has allowed us to analyze ctDNA beyond *EGFR*. We believe that the added value of NGS as compared to other methods is its possible use when no tumor tissue is available. Prospective interventional studies testing the clinical impact of an early therapeutic switch based on ctDNA quantification at first evaluation are needed to fully validate our findings.

Supporting Information {#sec023}
======================

###### 

Detection of gene alterations in the plasma (grey) as compared to the tumor tissue (blue) at different time points: (A) baseline (T0), (B) first evaluation (E1), and (C) time of progression (ToP).

(TIF)
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Click here for additional data file.

###### Prognostic value of ctDNA concentration.

\(A\) PFS and (B) OS according to tertiles of baseline ctDNA concentration.

(TIF)
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Click here for additional data file.

###### Prognostic of ctDNA positivity at first evaluation (E1).

OS according to E1 ctDNA status in the subgroup of (A) KRAS-mutated patients, (B) TP53-mutated patients, (C) EGFR-mutated patients, and (D) patients with more than one mutated gene.

(TIF)
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Click here for additional data file.

###### ctDNA evolution in 59 patients with evaluable ctDNA at T0, E1, and ToP.

At the time points, 4 patients had negative ctDNA. Time of tumor progression occurred at E1 for 11 patients, which is indicated by a cross.

(TIF)
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###### DNA used as internal controls for dPCR.
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###### dPCR reagent components and assay mix details.
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###### dPCR thermocycling conditions.
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###### Effect of patient and tumor baseline characteristics on PFS (*n* = 109).
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###### Translated study protocol.
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Click here for additional data file.

###### Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist.

(DOC)

###### 

Click here for additional data file.
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BPER

:   base-position error rate

ctDNA

:   circulating tumor DNA

dPCR

:   digital PCR

E1

:   first evaluation

FFPE

:   formalin-fixed, paraffin-embedded

HR

:   hazard ratio

MAF

:   mutant allele fraction

NGS

:   next-generation sequencing

NSCLC

:   non-small cell lung cancer

OR

:   odds ratio

OS

:   overall surviva

PFS

:   progression-free survival

RECIST

:   Response Evaluation Criteria in Solid Tumors

STROBE

:   Strengthening the Reporting of Observational Studies in Epidemiology

T0

:   baseline

ToP

:   time of tumor progression

UICC

:   Union for International Cancer Control
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